SMTL ID : 6acb.1

Crystal structure of PDE5 in complex with inhibitor LW1805

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.80 Å

Oligo State

monomer

Ligands

1 x SO4: SULFATE ION(Non-functional Binders)

SO4.1: 7 residues within 4Å: Chain A: H.79, H.83, D.120, D.230, L.231 Ligands: ZN.2, 9T9.4 2 PLIP interactions: 2 interactions with chain A Salt bridges: A:H.79, A:H.83

1 x ZN: ZINC ION(Non-covalent)

ZN.2: 6 residues within 4Å: Chain A: H.83, H.119, D.120, D.230 Ligands: SO4.1, MG.3 5 PLIP interactions: 4 interactions with chain A, 1 Ligand-Water interactions Metal complexes: A:H.83, A:H.119, A:D.120, A:D.230, H2O.1

1 x MG: MAGNESIUM ION(Non-covalent)

MG.3: 4 residues within 4Å: Chain A: H.119, D.120, T.189 Ligands: ZN.2 5 PLIP interactions: 1 interactions with chain A, 4 Ligand-Water interactions Metal complexes: A:D.120, H2O.1, H2O.1, H2O.1, H2O.1

1 x 9T9: 3-[(2H-1,3-benzodioxol-5-yl)methyl]-8-fluoro-6-{[2-(4-methylpiperazin-1-yl)ethyl]amino}-1-(1,3-thiazol-2-yl)[1]benzopyrano[2,3-c]pyrrol-9(2H)-one(Non-covalent)

9T9.4: 12 residues within 4Å: Chain A: V.126, L.191, L.231, I.234, A.249, F.252, F.253, I.279, M.282, Q.283, F.286 Ligands: SO4.1 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:F.252, A:M.282, A:F.286 Hydrogen bonds: A:Q.283, A:Q.283 pi-Stacking: A:F.286, A:F.286

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Wu, D. et al., Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension. J. Med. Chem. (2018)

Release Date

2018-09-19

Peptides

cGMP-specific 3',5'-cyclic phosphodiesterase: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

cGMP-specific 3',5'-cyclic phosphodiesterase

Related Entries With Identical Sequence